The JV, called Maqgen, will be based in Chengdu, Sichuan Province, and is owned 60 percent by Maccura and 40 percent by Qiagen.
Respondents to a 2013 survey described changes in the way hereditary breast and ovarian cancer risk is assessed, interpreted, and conveyed to patients following the court decision.
Thermo is launching a program to develop its NGS Oncomine products into companion diagnostics, with the University Hospital Basel as its first partner.
Gencurix aims to achieve US FDA 510(k) clearance for its GenesWell BCT breast cancer prognostic test next year.
Groups from Austria, Spain, Germany, and the US demonstrated that the GeneReader can reliably detect cancer mutations in tissue and liquid biopsy samples.
Such analyses can help researchers pinpoint how various cancers evolve and determine the best kinds of tests to use to find certain disease information.
In a conference call to discuss the firm's fourth-quarter and full-year earnings, senior management highlighted recent developments and outlined expectations for 2017.
The activity follows a recent financing round that has enabled OncoDNA to build out its sales team as it courts new clients.
OncoDNA has launched two new precision cancer medicine projects, the budgets for which total €16 million and are being supported in part by the Belgian Walloon Region.
The team will use the new research grant to further develop the Stockholm3 prostate cancer test and to design follow-on diagnostics to help treat patients with the disease.
A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.
In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.